Patents by Inventor Randall W. Nelson

Randall W. Nelson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20170003305
    Abstract: Disclosed is a composition that synergistically prevents proteolysis or modification of peptides in sampled biological fluids using sulfonyl fluoride family protease inhibitors at high concentrations combined with at least one additional protease inhibitor of a different type, preferably a broad spectrum protease inhibitor, and a chelator. A preferred embodiment uses AEBSF at 10 mM, Benzamidine at 20 mM and EDTA as the chelator. The disclosed composition may be combined with other protease inhibitors to further modulate its specificity, for instance to additionally target acidic proteases. Additional protease inhibitors, reducing agents, stabilizers and buffering agents may be combined with the disclosed compositions in devices for sampling or testing biological fluids for levels of peptides of interest, or methods therefore. The disclosed devices, compositions and methods are of particular use in sampling and testing for the level of natriuretic peptides.
    Type: Application
    Filed: September 19, 2016
    Publication date: January 5, 2017
    Applicant: CRIMSON U.S. ASSETS LLC
    Inventors: Ute Schellenberger, Eric E. Niederkofier, Urban A. Kiernan, Jessica O'Rear, Randall W. Nelson
  • Patent number: 9482677
    Abstract: Disclosed is a composition that synergistically prevents proteolysis or modification of peptides in sampled biological fluids using sulfonyl fluoride family protease inhibitors at high concentrations combined with at least one additional protease inhibitor of a different type, preferably a broad spectrum protease inhibitor, and a chelator. A preferred embodiment uses AEBSF at 10 mM, Benzamidine at 20 mM and EDTA as the chelator. The disclosed composition may be combined with other protease inhibitors to further modulate its specificity, for instance to additionally target acidic proteases. Additional protease inhibitors, reducing agents, stabilizers and buffering agents may be combined with the disclosed compositions in devices for sampling or testing biological fluids for levels of peptides of interest, or methods therefore. The disclosed devices, compositions and methods are of particular use in sampling and testing for the level of natriuretic peptides.
    Type: Grant
    Filed: February 27, 2008
    Date of Patent: November 1, 2016
    Assignee: SCIOS INC.
    Inventors: Ute Schellenberger, Eric E Niederkofler, Urban A Kieman, Randall W. Nelson, Jessica O'Rear
  • Publication number: 20160003841
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Application
    Filed: September 14, 2015
    Publication date: January 7, 2016
    Inventors: Kemmons Tubbs, Karl F. Gruber, Randall W. Nelson
  • Patent number: 9134306
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Grant
    Filed: November 4, 2013
    Date of Patent: September 15, 2015
    Assignee: Intrinsic Bioprobes, Inc.
    Inventors: Kemmons Tubbs, Karl F. Gruber, Randall W. Nelson
  • Publication number: 20140193311
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Application
    Filed: November 4, 2013
    Publication date: July 10, 2014
    Applicant: Intrinsic Bioprobes, Inc.
    Inventors: Kemmons Tubbs, Karl F. Gruber, Randall W. Nelson
  • Patent number: 8574434
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: November 5, 2013
    Assignee: Intrinsic Bioprobes, Inc.
    Inventors: Kemmons Tubbs, Karl F. Gruber, Randall W. Nelson
  • Publication number: 20130217058
    Abstract: Methods are described for monitoring the amounts of PTH variants in a biological sample by digesting the sample to produce surrogate peptides specific to the targeted PTH variants, and detecting and quantifying the surrogate peptides by selective reaction monitoring (SRM) mass spectrometry, using a set of precursor-to-product ion transitions optimized for sensitivity and selectivity. The PTH variants, or a portion thereof, may be concentrated in the sample by means of immunoaffinity capture or other suitable technique. The mass spectrometric method described herein enables the concurrent measurement of peptides representative of a plurality of targeted PTH variants in a single assay.
    Type: Application
    Filed: February 25, 2013
    Publication date: August 22, 2013
    Inventors: Mary Frances LOPEZ, David A. SARRACINO, Amol PRAKASH, Randall W. NELSON, Paul ORAN, Bryan E. KRASTINS, Taha REZAI
  • Publication number: 20130217630
    Abstract: The invention relates to PTH variants and uses thereof in the detection, diagnosis, and treatment of various disease states.
    Type: Application
    Filed: October 26, 2011
    Publication date: August 22, 2013
    Applicant: ARIZONA BOARD OF REGENTS, a body corporate of the State of Arizona, acting for an on behalf of Arizo
    Inventors: Randall W. Nelson, Paul Oran
  • Patent number: 8486713
    Abstract: Rapid mass spectrometric immunoassay methods for detecting and/or quantifying antibody and antigen analytes utilizing affinity capture to isolate the analytes and internal reference species (for quantification) followed by mass spectrometric analysis of the isolated analyte/internal reference species. Quantification is obtained by normalizing and calibrating obtained mass spectrum against the mass spectrum obtained for an antibody/antigen of known concentration.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: July 16, 2013
    Assignee: Intrinsic Bioprobes, Inc.
    Inventors: Randall W. Nelson, Peter Williams, Jennifer Reeve Krone
  • Publication number: 20130053257
    Abstract: The present invention relates to multiplexed assays for the diagnosis of RANTES-based disorders. Essentially, a single, high information content RANTES assay is used to simultaneously determine an individual's disposition towards a disease as well as the onset and progression of the disease (or response to treatment). As such, the (single) analysis has the particular advantage of always producing data useful in the longitudinal monitoring (of individuals) for a disease. In specific example, the discovery relates RANTES isoforms with the predisposition, onset and progression of T2D, CHF, MI, and cancer. All isoforms of particular blood and urine borne proteins—containing protein phenotype data—are monitored in a single, high throughput analysis able to acquire data relevant to the stages of the disease (or treatment).
    Type: Application
    Filed: February 7, 2011
    Publication date: February 28, 2013
    Inventors: Paul E. Oran, Randall W. Nelson
  • Patent number: 8383417
    Abstract: Methods are described for monitoring the amounts of PTH variants in a biological sample by digesting the sample to produce surrogate peptides specific to the targeted PTH variants, and detecting and quantifying the surrogate peptides by selective reaction monitoring (SRM) mass spectrometry, using a set of precursor-to-product ion transitions optimized for sensitivity and selectivity. The PTH variants, or a portion thereof, may be concentrated in the sample by means of immunoaffinity capture or other suitable technique. The mass spectrometric method described herein enables the concurrent measurement of peptides representative of a plurality of targeted PTH variants in a single assay.
    Type: Grant
    Filed: December 22, 2009
    Date of Patent: February 26, 2013
    Assignees: Thermo Finnigan, LLC, Intrinsic Bioprobes, Inc.
    Inventors: Mary Frances Lopez, David A. Sarracino, Amol Prakash, Randall W. Nelson, Paul Oran, Bryan E. Krastins, Taha Rezai
  • Patent number: 8372279
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: February 12, 2013
    Assignee: Intrinsic Bioprobes, Inc.
    Inventors: Kemmons Tubbs, Karl F. Gruber, Randall W. Nelson
  • Publication number: 20120171782
    Abstract: Rapid mass spectrometric immunoassay methods for detecting and/or quantifying antibody and antigen analytes utilizing affinity capture to isolate the analytes and internal reference species (for quantification) followed by mass spectrometric analysis of the isolated analyte/internal reference species. Quantification is obtained by normalizing and calibrating obtained mass spectrum against the mass spectrum obtained for an antibody/antigen of known concentration.
    Type: Application
    Filed: March 15, 2012
    Publication date: July 5, 2012
    Inventors: Randall W. Nelson, Peter Williams, Jennifer Reeve Krone
  • Publication number: 20120085692
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Application
    Filed: December 8, 2011
    Publication date: April 12, 2012
    Inventors: Kemmons A. Tubbs, Karl F. Gruber, Randall W. Nelson
  • Patent number: 8075767
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Grant
    Filed: February 26, 2011
    Date of Patent: December 13, 2011
    Assignee: Intrinsic Bioprobes, Inc.
    Inventors: Kemmons A. Tubbs, Karl F. Gruber, Randall W. Nelson
  • Publication number: 20110250618
    Abstract: The present invention is directed to novel biomarkers and combinations thereof. The present invention also provides assays and data evaluation methods related to the detection and monitoring of diseases, particularly, diabetes. In particular, the biomakers in accordance with the present invention include, but are not limited to, modified forms of nominally wild-type proteins, such as Gc-Globulin or GcG (also known as Vitamin D binding protein), beta-2-microglobulin (b2m), cystatin C (cysC), Albumin and Hem A&B. Particular forms of diabetes contemplated by the methods of the present invention include, but are not limited to, type 1 diabetes (T1D), type 2 diabetes (T2DM), pre-T1D and pre-T2DM. The present invention also provides methods of detecting multiple biomarkers in a single assay and to employ data evaluation methods that is able to accurately use these data in the determination and monitoring of diseases, such as diabetes.
    Type: Application
    Filed: March 17, 2009
    Publication date: October 13, 2011
    Applicant: Arizona Board of Regents, for and on behalf of Arizona State University
    Inventors: Randall W. Nelson, Chad R. Borges, Paul Oran
  • Patent number: 8030011
    Abstract: Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included.
    Type: Grant
    Filed: October 18, 2010
    Date of Patent: October 4, 2011
    Assignee: Intrinsic Bioprobes, Inc.
    Inventors: Urban A. Kiernan, Dobrin Nedelkov, Randall W. Nelson
  • Publication number: 20110192778
    Abstract: Described is an affinity microcolumn comprising a high surface area material, which has high flow properties and a low dead volume, contained within a housing and having affinity reagents bound to the surface of the high surface area material that are either activated or activatable. The affinity reagents bound to the surface of the affinity microcolumn further comprise affinity receptors for the integration into high throughput analysis of biomolecules.
    Type: Application
    Filed: February 26, 2011
    Publication date: August 11, 2011
    Inventors: Kemmons A. Tubbs, Karl F. Gruber, Randall W. Nelson
  • Publication number: 20110151568
    Abstract: Methods are described for monitoring the amounts of PTH variants in a biological sample by digesting the sample to produce surrogate peptides specific to the targeted PTH variants, and detecting and quantifying the surrogate peptides by selective reaction monitoring (SRM) mass spectrometry, using a set of precursor-to-product ion transitions optimized for sensitivity and selectivity. The PTH variants, or a portion thereof, may be concentrated in the sample by means of immunoaffinity capture or other suitable technique. The mass spectrometric method described herein enables the concurrent measurement of peptides representative of a plurality of targeted PTH variants in a single assay.
    Type: Application
    Filed: December 22, 2009
    Publication date: June 23, 2011
    Inventors: Mary Frances Lopez, David A. Sarracino, Amol Prakash, Randall W. Nelson, Paul Oran, Bryan E. Krastins, Taha Rezai
  • Publication number: 20110124122
    Abstract: Presented herein are novel blood plasma/serum biomarkers related to cardiovascular disease. These newly identified biomarkers create the basis for multiple (single) assays using traditional bioassay technologies and when used in combination yield exceptional clinical sensitivity and specificity in the determination of myocardial infarction (MI). A multiplexed, mass spectrometric immunoassay (MSIA) able to simultaneously assay for the new/novel biomarkers as well other MI markers is also presented. Means and methods for evaluating data generated using multiple biomarkers in order to validate findings and further the use of the multiplexed MI assay in clinical, diagnostic and therapeutic uses is also included.
    Type: Application
    Filed: October 18, 2010
    Publication date: May 26, 2011
    Inventors: Urban A. Kiernan, Dobrin Nedelkov, Randall W. Nelson